Existing systems adapted and automated so zero development risk. Integrate into existing pathway management tools to deliver the evidence-based, risk stratification needed.
Advanced, evidence-based assessments
Our risk assessment is built on the POSSUM methodology developed by our founder but evolved over 12 years around our 350m patient dataset.
Risk-assessing every patient
For risk of mortality and complications by type, the impact of wait list deterioration on mortality and complication risk, hospital based decision criteria etc.
Built on assessment of clinical urgency
Supports legal requirements to prioritise on clinical urgency.
Highest levels of information governance
C2-Ai is a proud partner of NHS Digital with full access to national HES data built around our highest level IG processes, MHRA and ISO approvals.
Direct cost savings
Through up to 50% reduction in harm and mortality.
Saves 6.25 weeks per surgeon
Reducing the up to 15 minutes per patient every time list is triaged and totalling up to 1,000 person hours that could be used to get though operations more quickly.
UK Minister in Parliament
Companies like Cambridge-based C2-AI.. are leading the way in the UK’s cutting edge, health tech sector. C2-AI save lives by predicting avoidable harm and mortality so they free up capacity in intensive care units for COVID-19 patients.
C2-Ai is one of 10 Essential Digital Health Responses to Covid19 and has won multiple awards e.g. COGX Best Innovation for Covid-19 and Medtech Company of the Year.